Combinatorial peptides directed to inhibitory antibodies against human blood clotting factor VIII

Summary

The development of antibodies against blood clotting factorVIII is a major complication affecting 20–30% of hemophilia A patients receiving replacement with FVIII concentrates. This study investigated generating peptides acting as broadly neutralizing agents to block factor VIII antibodies. These peptides were selected from dual positional scanning decapeptide libraries on cellulose membranes. From this library comprising 6.8×10¹² peptides we selected 468 peptides for further screening rounds. Finally we identified two decapeptides with the ability to block 8 out of 10 inhibitory antibodies from sera of patients with FVIII inhibitors demonstrated by competition assays. Sequence alignment of the peptides showed similarity with several domains in the FVIII molecule demonstrating the mimotope nature of the selected peptides. Our results show the efficiency of the combinatorial library approach and show the potential of combinatorial peptides to compete out polyclonal inhibitor IgG from a broad range of patients’ sera. Combinatorial peptides could be novel and highly effective drug candidates for alternative treatment in patients with factor VIII inhibitors.

Keywords

Hemophilia - factor VIII inhibitor - mimotopes - combinatorial peptides

• References

• 1 Vehar GA, Keyt B, Eaton D. et al. Structure of human factor VIII. Nature 1984; 312: 337-42.
• 2 Schwarzinger I, Pabinger I, Korninger C. et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987; 24: 241-5.
• 3 Ehrenforth S, Kreuz W, Scharrer I. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
• 4 Hoyer LW, Gawryl MS, de la Fuente B. Immunochemical characterization of factor VIII inhibitors. Prog Clin Biol Res 1984; 150: 73-85.
• 5 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
• 6 Negrier C, Goudemand J, Sultan Y. et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
• 7 Hedner U. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Dis Mon 2003; 49: 39-48.
• 8 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972; 1: 75-95.
• 9 Scandella DH, Nakai H, Felch M. et al. In hemophilia a and autoantibody inhibitor patients: the factor viii a2 domain and light chain are most immunogenic. Thromb Res 2001; 101: 377-85.
• 10 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-3.
• 11 Boisson-Vidal C, Haouam M. et al. Polystyrene derivatives as candidates for extracorporeal adsorption of Factor VIII antibodies in the management of haemophiliac patients. Vox Sang 2002; 83: 214-21.
• 12 Jansen M, Schmaldienst S, Banyai S. et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112: 91-7.
• 13 Reding MT, Wu H, Krampf M. et al. CD4+ T cells specific for factor VIII as a target for specific suppression of inhibitor production. Adv Exp Med Biol 2001; 489: 119-34.
• 14 Reding MT, Okita DK, Diethelm-Okita BM. et al. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003; 8: 1777-84.
• 15 Salooja N, Kemball-Cook G, Tuddenham E. et al. Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX. PG – 839–42. Br J Haematol 2002; 118: 839-42.
• 16 Stasi R, Brunetti M, Stipa E. et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
• 17 Frank R. Spot-synthesis: An easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 1992; 48: 9217-32.
• 18 Geysen HM, Rodda SJ, Mason TJA. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol Immunol 1986; 23: 709-15.
• 19 Grothaus MC, Srivastava N, Smithson SL. et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 2000; 18: 1253-63.
• 20 Bracci L, Lozzi L, Lelli B. et al. Mimotopes of the nicotinic receptor binding site selected by a combinatorial peptide library. Biochemistry 2001; 40: 6611-9.
• 21 Albert T, Lange S, Oldenburg J. et al. [Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries]. Haemostaseologie 2003; 23: 13-7.
• 22 Kasper CK, Aledort L, Aronson D. et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
• 23 Kramer A, Reineke U, Dong L. et al. Spot synthesis: observations and optimizations. J Pept Res 1999; 54: 319-27.
• 24 Laune D, Molina F, Ferrieres G. et al. Application of the Spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding. J Immunol Methods 2002; 267: 53-70.
• 25 Dooley CT, Houghten RA. Synthesis and screening of positional scanning combinatorial libraries. Methods Mol Biol 1998; 87: 13-24.
• 26 Lien S, Lowman HB. Therapeutic peptides. Trends Biotechnol 2003; 21: 556-62.
• 27 Aina OH, Sroka TC, Chen ML. et al. Therapeutic cancer targeting peptides. Biopolymers 2002; 66: 184-99.
• 28 Andersson L, Blomberg L, Flegel M. et al. Largescale synthesis of peptides. Biopolymers 2000; 55: 227-50.
• 29 Hinds KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002; 54: 505-30.
• 30 Fijnvandraat K, Celie PH, Turenhout EA. et al. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998; 91: 2347-52.
• 31 Healey JF, Barrow RT, Tamim HM. et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701-9.
• 32 Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994; 94: 1496-505.
• 33 Gilles JG, Vanzieleghem B, Saint-Remy JM. Factor VIII Inhibitors. Natural autoantibodies and anti-idiotypes. Semin Thromb Hemost 2000; 26: 151-5.
• 34 Lacroix-Desmazes S, Bayry J, Misra N. et al. The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A. Haemophilia 2002; 2: 55-9.
• 35 Saint-Remy JM, Jacquemin MG, Gilles JG. Antiidiotypic antibodies: from regulation to therapy of factor VIII inhibitors. Vox Sang 1999; 77: 21-4.
• 36 Lacroix-Desmazes S, Misra N, Bayry J. et al. Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. Haemophilia 2002; 8: 273-9.
• 37 Villard S, Piquer D, Raut S. et al. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem 2002; 277: 27232-9.
• 38 Villard S, Lacroix-Desmazes S, Kieber-Emmons T. et al. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood 2003; 102: 949-52.
• 39 Muhle C, Schulz-Drost S, Khrenov AV. et al. Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display. Thromb Haemost 2004; 91: 619-25.